Peru's National Institute of Health (INS) — through its Directorate of Health Research and Innovation (DIIS, formerly OGITT) — authorizes clinical trials under a 40-business-day statutory target (60 business days for biologics or cases needing technical-commission review) — targets that derive from the drug-trial framework and that novel FIH device studies may exceed — while DIGEMID regulates medical devices under the Ministry of Health (MINSA). With accredited ethics committee review, ISO 14155 alignment, and bioaccess®'s coordination, sponsors generate FDA-submissible data at ~30% lower cost than US/EU programs.
Peru offers a defined, predictable regulatory pathway for clinical research. The National Institute of Health (INS), through its Directorate of Health Research and Innovation (DIIS, formerly OGITT), authorizes clinical trials under a 40-business-day statutory target — extended to 60 business days for biologics or cases that require technical-commission review. These targets derive from the drug-trial framework, and novel FIH device studies may take longer.
Medical devices are regulated by DIGEMID under the Ministry of Health (MINSA), and DIGEMID also issues the investigational device import authorization required to ship product into the country. An accredited ethics committee must approve each study. All work is conducted under ISO 14155 and the Declaration of Helsinki.
bioaccess® coordinates INS/DIIS submissions, DIGEMID interactions where applicable, ethics committee review, site qualification, and monitoring so sponsors get FDA-quality first-in-human data at roughly 30% lower cost than a comparable US or EU program. Peru fits well within multi-country LATAM programs.
The National Institute of Health (INS) is Peru's authority for clinical trial authorization. Its Directorate of Health Research and Innovation (DIIS, formerly OGITT) reviews submissions under a 40-business-day statutory target — extended to 60 business days for biologics or cases that require review by a technical commission. These windows derive from the drug-trial framework, and novel FIH device studies may take longer. bioaccess® prepares complete INS dossiers.
Medical devices in Peru are regulated by DIGEMID (Dirección General de Medicamentos, Insumos y Drogas) under the Ministry of Health (MINSA). bioaccess® coordinates DIGEMID interactions, including the investigational device import authorization required for shipping product into Peru, and integrates them with the INS trial authorization.
Every clinical study in Peru must be approved by an accredited ethics committee before enrollment can begin. Ethics review follows ISO 14155 (the FDA-recognized GCP standard for medical device investigations) and evaluates scientific merit, risk-benefit balance, informed consent, and patient protection. bioaccess® coordinates ethics submissions with experienced partner committees.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Peru for IDE submissions and marketing applications when studies are conducted under ISO 14155 with proper INS authorization and ethics approval. bioaccess® designs every protocol for FDA submission from day one.
| Metric | Peru 🇵🇪 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Trial authorization | INS (DIIS): 40-business-day statutory target | 6–12 months (IDE + IRB) | 3–6 months (per-country CA + EC) |
| Regulatory authorities | INS (trials) + DIGEMID (devices) | FDA | EMA / national CAs |
| Ethics review | Accredited ethics committee | Local IRBs | Per-country ECs |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Cost vs. US program | ~30% lower | Baseline | ~15–25% lower |
| Time zone vs. US East Coast | Same (EST) / near | Same | +5 to +6 hours |
Regulatory details reflect published national frameworks; timelines and costs vary by device complexity, therapeutic area, and monitoring requirements. bioaccess® confirms the current pathway for each program.
The National Institute of Health (INS), through its Directorate of Health Research and Innovation (DIIS, formerly OGITT), authorizes clinical trials in Peru.
INS (DIIS) operates under a 40-business-day statutory target — extended to 60 business days for biologics or cases requiring technical-commission review. These targets derive from the drug-trial framework, and novel FIH device studies may take longer.
DIGEMID (Dirección General de Medicamentos, Insumos y Drogas), under the Ministry of Health (MINSA), is Peru's medical device regulator.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Peru when studies are conducted under ISO 14155 with proper INS authorization and accredited ethics committee approval. bioaccess® designs protocols for FDA submission from the start.
Peru programs typically run ~30% lower than a comparable US or EU program. Actual cost depends on device complexity, indication, monitoring intensity, and sample size — bioaccess® scopes each program individually.
Peru combines a defined INS pathway with a 40-business-day statutory target (drug-trial framework; novel FIH device studies may take longer), DIGEMID as a clear device regulator, accredited ethics review under ISO 14155, and ~30% lower program cost than US/EU baselines.
All countries we serve · Contact bioaccess® · First-in-Human CRO